Linklaters Wins “Healthcare/Life Sciences Deal of the Year (Over $500M)” at 2022 M&A Advisor Awards for the Merger of Union Acquisition Corp II and Procaps

The M&A Advisor awarded Linklaters with the “Healthcare/Life Sciences Deal of the Year (Over $500M)” at the 21st Annual M&A Advisor Awards, a ceremony that recognizes the most significant transactions of the year, for the merger between Union Acquisition Corp II, a special purpose acquisition company (SPAC), and Procaps a leading global pharmaceutical technology and healthcare company based in Latin America with a presence in 13 countries and reach in 50 markets with a wide portfolio of patents and trademarks.

 

Additionally, The M&A Advisor recognized M&A partners Pierre-Emmanuel Perais and Clara Pang as 2022 Emerging Leaders for their achievements and leadership in M&A and accomplishments in business and service to the community. The awards gala took place on Tuesday, November 15th at the New York Athletic Club. The M&A Advisor was founded in 1998 to offer insights, intelligence and recognition on mergers and acquisitions.

Merger of Union Acquisition Corp II and Procaps to create Procaps Group, S.A.

Linklaters advised Union Acquisition Corp. II (UAC II) on the successful closing of its US$1.125bn business combination with Crynssen Pharma Group Ltd (Procaps) and related listing of new holding company Procaps Group, S.A. on Nasdaq under “PROC”. In connection with the transaction, UAC II also completed a US$100mm private investment in public equity (PIPE) offering. The transaction is the first Latin American SPAC to have an over-subscribed PIPE. It is also one of the few de-SPACs between a U.S.-listed SPAC and a Latin American business. The Linklaters team was led by partners Matthew Poulter, Pierre-Emmanuel Perais and Jeffrey Cohen.